Edgar Engleman

Edgar Engleman

Founder presso BOLT BIOTHERAPEUTICS, INC.

Patrimonio netto: 2 M $ in data 31/03/2024

78 anni
Health Technology
Consumer Services
Finance

Profilo

Edgar Engleman, M.D.
is a founding member and Chief Scientific Advisor of Vivo Capital.
Dr. Engleman is a Professor of Pathology and Medicine at the Stanford University School of Medicine, where he established and oversees the Stanford Blood Center, directs his immunology research team, and co-directs the Tumor Immunology and Immunotherapy Research Programs at the Stanford Cancer Institute.
He is an inventor of multiple patented technologies, has authored more than 300 publications in medical and scientific journals, and trained more than 100 graduate and postgraduate students.
Dr. Engleman is the lead inventor of the technology underlying a cancer immunotherapy known as Provenge (Sipulucel-T), which was shown to extend the life of patients who suffer from metastatic prostate cancer.
Provenge is the first in the class of personalized immunotherapeutic agents to be FDA approved for the treatment of cancer.
He is also the lead inventor of the technology underlying the immunotherapies in development at Bolt Biotherapeutics.
Dr. Engleman is the founder or cofounder of a number of biotech companies including Cetus Immune (acquired by Novartis), Genelabs (acquired by GlaxoSmithKline), Dendreon (acquired by Sanpower), and Vivo portfolio companies Medeor, Bolt, and Tranquis.
He currently serves on the boards of Bolt (BOLT) and several private companies including Tranquis, Synapse and Ossium.
He previously served on the boards of REGENEXBIO (RGNX), Eiger (EIGR), Soleno (SLNO), Intermune (ITMN, acquired by Roche), Insmed (INSM), Prestwick (acquired by Biovail) and Semnur (acquired by Sorrento (SRNE).
He received his BA from Harvard College and earned his M.D.
from Columbia University School of Medicine.
In 2017, he received the CABS K Fong Prize in Life Sciences for his biomedical discoveries and contributions.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
12/06/2023 1 278 227 ( 3.35% ) 2 M $ 31/03/2024

Posizioni attive di Edgar Engleman

SocietàPosizioneInizio
BOLT BIOTHERAPEUTICS, INC. Founder 22/01/2015
Founder 01/01/1996
Director/Board Member -
Vivo Co-Invest (S) LP Director/Board Member -
Founder -
Director/Board Member -
Stanford University School of Medicine Corporate Officer/Principal 01/01/1990
Tutte le posizioni attive di Edgar Engleman

Precedenti posizioni note di Edgar Engleman

SocietàPosizioneFine
SOLENO THERAPEUTICS, INC. Director/Board Member 31/12/2017
EIGER BIOPHARMACEUTICALS, INC. Director/Board Member 18/09/2017
░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
░░░░░░ ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
Vedi nel dettaglio l'esperienza di Edgar Engleman

Formazione di Edgar Engleman

Harvard University Undergraduate Degree
Columbia University College of Physicians & Surgeons Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Edgar Engleman

Relazioni

100 +

Relazioni di 1° grado

29

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa5
INSMED INCORPORATED

Health Technology

SOLENO THERAPEUTICS, INC.

Health Technology

REGENXBIO INC.

Health Technology

BOLT BIOTHERAPEUTICS, INC.

Health Technology

EIGER BIOPHARMACEUTICALS, INC.

Health Technology

Aziende private21

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Electronic Technology

Health Technology

Health Technology

Health Technology

Health Services

Cetus Immune

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Vivo Co-Invest (S) LP

Vedi le connessioni aziendali
  1. Borsa valori
  2. Insiders
  3. Edgar Engleman